Lantheus/$LNTH
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Primary listing
Employees
808
Headquarters
Website
Lantheus Metrics
BasicAdvanced
$3.5B
22.20
$2.39
-
-
Price and volume
Market cap
$3.5B
52-week high
$111.29
52-week low
$47.25
Average daily volume
1.4M
Financial strength
Current ratio
2.667
Quick ratio
2.206
Long term debt to equity
55.268
Total debt to equity
50.822
Interest coverage (TTM)
17.43%
Profitability
EBITDA (TTM)
408.192
Gross margin (TTM)
62.23%
Net profit margin (TTM)
10.99%
Operating margin (TTM)
22.52%
Effective tax rate (TTM)
30.89%
Revenue per employee (TTM)
$1,890,000
Management effectiveness
Return on assets (TTM)
9.93%
Return on equity (TTM)
14.59%
Valuation
Price to earnings (TTM)
22.199
Price to revenue (TTM)
2.381
Price to book
3.15
Price to tangible book (TTM)
25.23
Price to free cash flow (TTM)
8.893
Free cash flow yield (TTM)
11.25%
Free cash flow per share (TTM)
5.974
Growth
Revenue change (TTM)
1.95%
Earnings per share change (TTM)
-60.26%
3-year revenue growth (CAGR)
23.94%
10-year revenue growth (CAGR)
17.69%
3-year earnings per share growth (CAGR)
16.27%
10-year earnings per share growth (CAGR)
10.73%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit
Business Wire4 days ago
LANTHEUS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Newsfile Corp4 days ago
LANTHEUS DEADLINE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Newsfile Corp5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $3.5B as of November 14, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 22.2 as of November 14, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of November 14, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) does not currently have a Beta indicator.